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We developed an AIDS vaccine for Western and West-Central Africa founded on HIV-1 subtype CRF02_AG. Rhesus macaques were
primed with Gag–Pol–Env-expressing plasmid DNA and boosted with a recombinant modified vaccinia virus Ankara (rMVA), expressing
matched proteins. Two DNA vaccine constructs (IC1-90 and IC48) that differed by point mutations in gag and pol were compared. IC1-90
produces primarily immature (core comprises unprocessed Pr55Gag) HIV-like particles (VLPs) and IC48 produces mature VLP with
processed Pr55Gag, immature VLP, and intracellular protein aggregates. Both vaccines raised significant cellular responses for Gag, Pol, and
Env. Approximate twofold higher ELISPOT responses to Gag and Env epitopes were observed for IC48 animals than for IC1-90 animals at
the peak post-MVA effector (P = 0.028) and late memory (P = 0.051) phases, respectively. Greater breadth for IC48-primed animals was
observed than for IC1-90-primed animals at peak response (P = 0.03). Our results indicated that the vaccines elicited high frequency T cell
responses and primed anti-Env antibody. They also suggest that expression of different forms of VLP has a significant effect on elicited
cellular and humoral immunity.
Published by Elsevier Inc.Keywords: Immunogenicity; Rhesus monkeys; CRF02_AG0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.06.014
i This study was carried out under an approved protocol in accordance
with guidelines set forth by the Centers for Disease Control and Prevention.
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Many novel candidates and approaches have been
developed in the pursuit to identify an effective human
immunodeficiency virus (HIV) vaccine. The induction of
strong cell-mediated immunity and broadly reactive anti-
envelope antibodies that can neutralize primary HIV-1 may
be necessary in the making of an effective HIV-1 vaccine,005) 21 – 32
D. Ellenberger et al. / Virology 340 (2005) 21–3222and the ideal vaccine may need to induce both T and B cell
responses. Plasmid DNA vaccination can elicit both
humoral and cellular immune responses (Tang et al., 1992;
Ulmer et al., 1993; Wolff et al., 1990) that protect
nonhuman primates against challenges with nonpathogenic
AIDS viruses (Boyer et al., 1997; Letvin et al., 1997) and
afford modest protection against disease from pathogenic
simian immunodeficiency virus (SIV) (Egan et al., 2000; Lu
et al., 1996).
Vaccines that have been designed to raise cellular
immunity can in some cases control virulent viral chal-
lenges and prevent the development of AIDS in rhesus
macaques (Amara et al., 2001; Barouch et al., 2000, 2001;
Rose et al., 2001; Shiver et al., 2002). Priming the immune
response with plasmid DNA followed by a recombinant
poxvirus booster such as the modified vaccinia virus
Ankara (Amara et al., 2001; Robinson et al., 2000) or a
VLP-protein boost plus IL-12/GM-CSF (O’Neill et al.,
2003; O’Neill et al., 2002) are two of the many different
approaches to raising cellular immunity. Including multiple
HIV-1 gene regions on the same vector augments the DNA
prime-MVA boost approach, as both gag and env responses
are important to protection against virus challenge (Amara
et al., 2002). Lacking this potential advantage are HIV-1
DNA vaccines that encode only Gag or encode Gag, Env,
and other viral proteins on separate DNA constructs
(Barouch et al., 2000, 2002; Kang et al., 1999). Escape
by HIV is possible when the immune response is driven by
a single dominant epitope (Barouch et al., 2002, 2003;
Mortara et al., 1998); thus, a multi-epitope or multi-protein
response appears advantageous.
It is well established that VLP assembly and release from
cells depend on proper intracellular protease regulation to
preserve the Gag polyprotein (Gottlinger et al., 1989;
Karacostas et al., 1993; Peng et al., 1989) and may be
observed upon transfection of Gag-only expression systems
(Huang et al., 2001; Kang et al., 1999; Schneider et al.,
1997). Previous studies demonstrated that alteration of the
25th residue of protease, from Asp (D) to Asn (N), resulted
in complete loss of protease activity (Gottlinger et al., 1989;
Kohl et al., 1988; Loeb et al., 1989). Furthermore, Jacobsen
et al. (1995) demonstrated that mutagenesis of protease at
positions 48 (G48V) and 90 (M90L) led to less efficient
enzymatic activity and delayed processing of the gag and
gag–pol polyproteins. Protease mutations at either amino
acid positions 48 and 90 delay, but do not abolish, protease
enzymatic activity, unlike the D25N mutation, and permit
production of infectious virus when present within an
otherwise wild-type provirus. A recent study suggested that
the two protease mutations at positions 48 and 90 are not
limiting, not only in terms of high-level production of HIV-1
proteins, but also with regard to assembly of VLPs
(Ellenberger et al., 2004).
One of the most promising HIV vaccines is the
heterologous prime-boost approach. The prime may consist
of a recombinant plasmid DNA or viral vector-expressingHIV proteins. The heterologous boost would be a recombi-
nant viral vector (poxvirus or adenovirus) or second viral
vector, optimizing the boost for the vaccine insert immu-
nogen and not the vector itself. Using the same recombinant
viral vector for the prime and boost may lead to a
diminished immune response similar to preexisting immun-
ity to the recombinant vector (Vogels et al., 2003). Priming
with a recombinant plasmid DNA and boosting with a
recombinant MVA enhances the cellular responses to a
common immunogen contained in both vectors (Amara et
al., 2001; Hanke et al., 1998; Schneider et al., 1998, 2001).
At the peak effector phase of the immune response to the
vaccine protocol, induced CD8 cells can reach very high
frequencies of total CD8 cells (Allen et al., 2000; Amara et
al., 2001; Horton et al., 2002).
We undertook this study to test the immunogenicity of
two HIV-1 recombinant subtype CRF02_AG DNA vaccines
boosted with an identical MVA in rhesus macaques. Both
DNAs expressed matched Gag–Pol–Env proteins and
produced enveloped noninfectious VLPs. The DNAs
differed on two accounts: product expression and safety
mutations. For IC48, additional safety mutations were added
and these include inactivating point mutations in packaging
sequences in both nucleocapsid zinc fingers and three
inactivating point mutations in RT which abrogate reverse
transcription and RNase H and strand transfer activities as
previously described (Ellenberger et al., 2004; Smith et al.,
2004a, 2004b). By introducing distinct point mutations
within Pol protease, the composition of the virus core was
changed; the IC1-90 core comprised unprocessed Pr55Gag
(immature VLP) and IC48 had processed Pr55Gag. Another
outcome of the IC48 protease mutation was the production
of multiple antigenic forms whereas IC1-90 had one form,
immature VLP. Verification that the additional point
mutations of gag and pol RT would not be detrimental to
expression and could be potentially introduced if needed for
reasons of safety was also evaluated. Both DNA/MVA
vaccines raised significant and broadly reactive CD4 and
CD8 T cell responses with high frequencies of IFN-g and
IL-2-producing T cells specific for Gag and Env, as
measured by ELISPOT and intracellular cytokine (ICC)
staining assays. The multi-protein, heterologous DNA/MVA
vaccine approach may induce protective immune recogni-
tion of HIV-1.Results
Vaccine immunogens
To assess the assembly of VLPs, transfection culture
supernatants were banded through a sucrose gradient and
subsequent fractions were examined for the presence of
Gag. Peak VLP fractions were analyzed by immunoblotting
using rabbit polyclonal anti-p24 antibody (Fig. 1A). Only
two Gag polyproteins, p55 and p41, were detected for IC1-
Fig. 1. Analysis of HIV-1-like particles. (A) Immunoblot analysis of sucrose-gradient-purified VLP using rabbit polyclonal anti-p24. The positions of HIV
precursors and products are indicated on the right. Fraction 9 from each gradient was separated by SDS–PAGE, transferred to nitrocellulose, and analyzed by
immunoblotting. Vaccine construct pGA1/IC25 (complete ablation of HIV protease activity) is included as reference (Ellenberger et al., 2004). (B) Summary of
protease mutations introduced in vaccine constructs and demonstrable expression products. (C) Transmission electron microscopy of VLPs and intracellular
protein aggregates in 293T cells transfected with vaccine constructs IC1–90 and IC48.
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for IC48. The presence of Gag p24 indicates cleavage of the
Gag polyprotein. As previously demonstrated, complete
inhibition of HIV protease activity by saquinavir (HIV-1
protease inhibitor) or vaccine construct IC25 (genetic
modification of protease activity) results in the Gag protein
being primarily p55, indicating no cleavage of the Gag
polyprotein (Ellenberger et al., 2004). A summary of the
vaccine constructs with corresponding protease mutations
which result in the production of assorted products,
including HIV protein aggregates and VLPs containing
complete to partial cleavage of Gag, is shown in Fig. 1B.
To confirm partial inhibition of protease activity permit-
ted VLP assembly and possible particle maturation, cells
transfected with protease-mutant vaccine constructs were
examined by electron microscopy (Fig. 1C). For IC1–90,immature VLPs were seen (Fig. 1C). These particles were
uniformly sized, abundant in number, and similar in
appearance (electron-dense shells and lucent centers) to
those formed by expression in the presence of saquinavir
and IC25 (Ellenberger et al., 2004). Budding structures and
numerous VLPs were also observed for IC48 (Fig. 1C).
However, two distinctive particle morphologies were
observed: VLPs with a spherical protein shell (immature)
and other particles with electron dense centers (mature).
Furthermore, the VLP with electron-dense centers had a
lean spherical protein shell, suggesting cleavage of Gag p55
and condensing of the viral core, comparable to mature HIV
particles. IC48-transfected cells were also observed to
contain intracellular aggregates of HIV proteins (Fig. 1C).
Total Gag expression was detected by antigen-capture
ELISA following 293T cell transfection; IC1–90 expression
Fig. 2. Temporal IFN-g ELISPOT responses for pGA1/IC1–90- and pGA1/
IC48 DNA-primed groups. Sixteen animals were tested against 19 peptide
pools. Symbols designate the total ELISPOT response of each individual
animal. The bold bar represents the arithmetic mean of each designated
group. Peak ELISPOT response (+42 weeks; 1 week after the MVA
booster), memory response (8 weeks after MVA), and late memory (26
weeks after MVA) are indicated. The background value (2 average of
negative control plus 10) was subtracted from the raw counts of the peptide
wells before conversion to 1 million PBMC.
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and 878 ng/ml, respectively. In the supernatant and cell
lysate, Gag protein levels were 77 and 54 ng/ml (IC1–90)
and 624 and 254 ng/ml (IC48), respectively. However, as
previously reported (Schneider et al., 1997), the detection
efficiency of Gag p55 was substantially less than that of Gag
p24. Therefore, quantification of total Gag protein of
transfection supernatants by Western blot analysis as
measured by phosphorimager demonstrated that IC1–90
expressed Gag protein to a level similar to IC48, 1771, and
1570 relative units. For IC1–90, the Gag protein was
primarily p55 (61% of the immunoreactive protein).
Production of Env protein was also detected by ELISA,
and IC1–90 and IC48 Env levels were similar, 696 and 665
ng/ml, respectively. A greater percentage of total Env
protein was detected in the supernatant for both constructs
(data not shown).
Preclinical safety testing
Three DNA primes at 0, 8, and 26 weeks and a single
rMVA booster at 41 weeks were administered in 1 ml by
IM needle injections. DNA priming was 0.6 mg of either
IC1–90 or IC48 per injection and MVA booster was at 1 
108 pfu. All 16 macaques received identical aliquots only
differing by the priming agent, IC1–90, or IC48. Physical
examinations, daily observations, measuring for weight,
hematology, and clinical chemistry were completed (data
not shown). No local redness or indurations at the injection
site were observed.
ELISPOT analysis
Vaccine-elicited T cells expanded rapidly after the MVA
booster (Fig. 2). Prior to the MVA booster, HIV-1-specific
ELISPOT responses were at, or below, our background for
detection following each of the DNA primes. Temporal
ELISPOT analyses revealed that the highest ELISPOT
response was 1 week after the MVA booster (Peak).
Frequencies up to 5300 spots per one million peripheral
blood mononuclear cells (PBMC) were found at the peak
response. This peak of specific cells underwent a threefold
contraction into the DNA/MVA memory pool (8 weeks
post-MVA). T cell responses contracted an additional
threefold at 26 weeks post-peak (late memory). Regardless
of the immune phase (peak, memory, or late-memory) total
ELISPOTS were greater for IC48-primed animals than IC1-
90-primed animals; the T cell responses for IC48 animals
were 2.2-fold greater (arithmetic mean) than IC1-90
animals. A random effects model using a linear regression
of the aggregate ELISPOT values on group and time
demonstrates that IC48 is higher than IC1-90, group effect
has P value = 0.002 in the model. Furthermore, at peak
response (P = 0.028) and late memory (P = 0.051),
significantly higher responses by IC-48-primed animals
were observed.At the peak response, both of tested plasmid DNAs
successfully primed the MVA booster for an anti-viral
IFN-g ELISPOT response to Gag, Pol, and Env sequences.
The analyses revealed greater than twofold differences
between the IC48 and IC1-90 primes (Fig. 3). The twofold
difference was significant and observed in all tested gene
regions of the virus, including Gag (P = 0.015), Pol (P =
0.047), and Env (P = 0.0003). For Pol and Env, the total
ELISPOT mean responses were less than the response
observed in Gag, but the twofold difference is evident. The
limited Tat response was expected as Tat was not a common
immunogen in the recombinant plasmid and rMVA.
A broad ELISPOT response for both Gag and Env was
present 1 week after the MVA booster (Fig. 4). Greater
breadth of response to peptide pools for IC48-primed
animals was observed than IC1-90-primed animals (P =
0.03). At the peak response, each of the 5 pools of Gag
peptides and 7 pools of Env peptides was recognized by at
least 3 of the immunized animals. On average per animal,
2.8 Gag and 2.9 Env peptide pools stimulated a cellular
response as measured by ELISPOT. Much lower frequen-
cies of responses were elicited for PR, RT, and Tat, but these
pools were recognized by at least one or more of the
animals. Four of the 16 animals recognized the one pool of
PR peptides, 7 recognized one of the 5 pools of RT peptides,
and one animal’s cells were stimulated by the pool of Tat
peptides.
Consistent with the height of the ELISPOT response, T
cells from IC48-primed animals recognized more peptide
pools than observed with IC1–90-primed animals (Table 1).
In the IC1–90 group, 6 of 8 animals responded to at least
Table 1
Average number of peptide pools per animal recorded as positive by
ELISPOT and intracellular cytokine staining analysis
Peptide
poole
ELISPOTa Intracellular cytokine stainingb
Peakc Memoryd CD8 CD4
IC1-90 IC48 IC1-90 IC48 IC1-90 IC48 IC1-90 IC48
Gag 2.5 3.1 2.1 2.5 1.1 1.25 2.9 3.0
Pol 1 1.8 0 0.5 NDf ND ND ND
Env 2.4 3.4 0.9 2.3 0.75 1.25 3.0 3.6
Total 6 8.3 3 5.3 1.9g 2.5g 5.9h 6.6h
a ELISPOT counts of twice the background (>100) were considered
positive.
b Combination of IFN-g and IL-2 expression.
c One week after MVA booster.
d Eight weeks after MVA booster.
e Gag, 5 pools; Pol, 6 pools (includes protease pool); Env, 7 pools.
f ND, not done.
g Average CD8+ cell response per animal, 2.2 pools.
h Average CD4+ cell response per animal, 6.25 pools.
Fig. 3. IFN-g ELISPOT responses at 1 week after the MVA booster.
Numbers indicate the arithmetic means for the response to the indicated
gene region. Designations below the panels indicate the gene and peptide
pool used for stimulation. Designations to the right of the panels indicate
the DNA prime group. Symbols indicate the individual animals. The
background value was subtracted before conversion to 1 million PBMC.
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recognized (Table 1, Fig. 4). For the IC48 group, 7 of 8
animals responded to at least two Gag pools with an overall
average of 3.1 pools being recognized. The Env response
was similar in the IC48 group where 7 of 8 animals
responded to at least two pools. In the IC1–90 group, only 6
of 8 animals responded to Env, recognizing at least one Env
pool. In the memory phase of the immune response, less
peptide pools stimulated T cell responses in all the
vaccinated animals, but IC48 animals responded to moreFig. 4. Breadth of peak ELISPOT responses for IC1–90- and IC48-primed
groups. Eight animals per vaccine group were tested against 19 peptide
pools (5 Gag, 6 Pol, and 7 Env, and 1 Tat). ELISPOT responses recorded as
positive for each peptide pool per animal are indicated.peptide pools than the IC1–90 group (5.3 vs. 3 pools),
respectively.
A broad response for both Gag and Env was retained 8
weeks post-MVA booster (Fig. 5). In the memory phase,
IC48-primed animals responded to more epitopes (P = 0.004)
than IC1–90-primed animals. Frequencies up to 2125 spots
per million PBMC were found at the memory phase. Fifteen
of the 16 animals recognized at least one pool of peptides.
Monkeys AC36 andM509, initially nonresponders at 1-week
post-MVA, were shown to recognize at least one Gag pool at
8 weeks post-MVA. Animal O2L remained nonresponsive to
the peptide pools. At the memory response, each of the 5
pools of Gag peptides and 5 of 7 Env peptide pools were
recognized by at least one of the immunized animals.
Intracellular cytokine analysis
To determine the frequencies of responding CD4 and
CD8 T cells, intracellular cytokine assays were performed
(Fig. 6). Peptide induction of IFN-g and IL-2 expression in
CD4 and CD8 lymphocytes was measured, and both tested
plasmid DNAs successfully primed the MVA booster. One
week following the MVA booster, peak responses were
observed as seen by ELISPOT analyses. Regardless of the
gene region, the response by IC48-primed animals was
significantly greater than IC1-90-primed animals: Env (P =
0.006) and Gag (P = 0.026). CD8 cells specific for Gag
epitopes expanded to frequencies as high as 2.6% of total
CD8 T cells in one animal. Intracellular cytokine staining
for IFN-g expression and IL-2 revealed an approximate
fourfold difference to Gag peptides between the DNA
plasmids; IC48 primed more CD8 cells than IC1–90. The
geometric mean of percent-specific CD8 cells was 0.54 vs.
0.14 for the IC48 group and IC1-90 group, respectively. A
twofold difference was detected in the Env region (0.28 vs.
0.14). The same ratios were observed regardless of the
expressed cytokine.
Fig. 5. ELISPOT responses determined 8 weeks after the MVA booster. Designations below the panels indicate individual animals and the DNA prime group
(8 animals/group). Stacked bars indicate ELISPOT response to individual peptide pools for each animal. White bars represent Gag peptide pools, filled dark
bars represent Pol peptide pools, and light-colored gray bars represent Env peptide pools. The background value was subtracted before conversion to 1 million
PBMC.
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expanded to frequencies as high as 0.5% of the total CD4 T
cells (Fig. 6). Statistical analyses revealed that a signifi-
cantly greater number of CD4 cells specific for Env epitopes
were observed for the IC48-primed animals than IC1–90
animals (P = 0.006). However, staining for IFN-g expres-
sion and IL-2 revealed a fourfold difference (0.39 vs. 0.11
geometric means) to Env peptides and twofold difference
(0.31 vs. 0.15) for Gag peptides between the DNA plasmids.
Overall, CD4 cell responses were significantly greater than
CD8 cell responses (P < 0.0001).
Based on Fig. 6 data, geometric means were determined
to compare specific cells (CD4 and CD8), cytokines
expressed (IFN-gand IL-2), and HIV gene regions. Peptide
induction of IL-2 expression in CD4 lymphocytes was
twofold greater than the percent-specific CD8 lymphocytes
(0.113 vs. 0.056 geometric mean). However, CD8 and CD4
cells were similar for IFN-g expression (0.089 vs. 0.078
geometric mean). In the Gag region, IFN-g expression was
significantly greater than IL-2 expression (P = 0.013), but
CD4-IL2, CD8-IL2, and CD8-IFN-g expressions were
significantly greater than CD4-IFN (P = 0.032).
The average number of peptide pools recorded as
positive by intracellular cytokine staining to include both
IFN-g and IL-2 expression were found to be relatively
comparable between DNA priming groups regardless of the
gene region (Table 1). At the peak immune response, IC1-90
animals would require a 31% and 11% increase in peptide
pool responses to equal the response of IC48 animals for
CD8 and CD4 cells, respectively. However, threefold more
peptide pools induced IFN-g and IL-2 expression in CD4
cells than CD8 cells (6.25 vs. 2.2 pools). This same
threefold ratio was observed for both IC1–90- and IC48-
primed animals.Antibody responses
The antibody response was strongly boosted by the
MVA. By Western blot analysis, negligible binding anti-
body was elicited by DNA priming, but 11 of 16 animals
(6 IC1–90 and 5 IC48 monkeys) showed Env reactivity
against an HIV-1 subtype AG virus lysate 3 weeks follow-
ing the MVA. All 11 reactive animals produced antibody
which detected Env gp120 and only one animal responded
to Gag p24. There was no difference between the two
groups of primed animals.
Anti-Env titers were determined for the vaccinated
animals by solid-phase Env ELISA. At 3 weeks post-
MVA, the average reciprocal titers were 1075(T1569) and
2119(T1898) for the IC1–90- and IC48-primed animals,
respectively. The titers fell to 953(T979) and 850(T563),
respectively, at 8 weeks after the booster. There was no
substantial difference observed between the two groups of
animals.
Tests for neutralizing antibody revealed very low levels
of activity for the primary isolate used for the vaccine; only
one animal scored positive. The primary isolate, a recombi-
nant HIV-1 subtype AG, was relatively resistant to
neutralization by many other sera and neutralizing mono-
clonal antibodies (data not shown). The neutralizing activity
of the plasma also did not score for HIV-1-MN (subtype B),
a laboratory-adapted isolate against HIV-1.Discussion
These studies reaffirm the utility of DNA- and MVA-
vectored vaccines for producing cellular immunity and
suggest that successive immunization with DNA and MVA
Fig. 6. Responding CD8 and CD4 cells determined by IFN-g and IL2
intracellular cytokine staining. (A) Percent-specific CD8 cells responding to
Gag and Env for individual animals at peak (1 week after the MVA
booster). The bold bar indicates the arithmetic mean height for the response
in each group. Designations above the panels specify the measured cytokine
(IFN-g or IL2) and designations below the panels specify the DNA prime
group. Symbols indicate the individual animals. (B) Percent-specific CD4
cells responding to Gag and Env for individual animals at peak (1 week
after the MVA booster). Designations above and below the panels are the
same as in panel A.
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can be an effective way of inducing broadly reactive CD4+
and CD8+ T cells. Furthermore, a novel and provocative
finding of this preclinical study is that in a DNA vector with
an HIV-1 vaccine insert capable of producing multiple
antigenic forms, including immature VLPs, mature VLPs,
and protein aggregates may significantly prime more anti-
Gag and anti-Env T cells, lasting beyond the peak effector
phase. We suggest that the production of multiple antigenic
forms, including VLPs with matured cores, may be an
improvement over one form such as immature VLPs with
unprocessed Pr55Gag, and potentially more robust than
single gene DNA constructs or single gene DNA plus
polyepitope constructs (Hanke et al., 2002; Mwau et al.,
2004). Furthermore, the introduction of additional safety
measures that ablates integration, reverse transcription, and
RNA packaging is not detrimental to immunogenicity.Given the lack of understanding of correlates of immune
protection and the basic biology of HIV disease, a vaccine
that generates a broadly reactive response and induces a
sizeable pool of long-lasting, protective memory T cells of
both CD4 and CD8+ T cells may be practical and effica-
cious. Many DNA vaccines have been developed and tested
in either preclinical or human trails, but not all DNA
vaccines are alike. DNA vaccines may encode only Gag or
encode Gag, Env, and other viral proteins on separate DNA
constructs or Gag plus a string of multiple CTL epitopes
(Barouch et al., 2000, 2002; Kang et al., 1999; Mwau et al.,
2004). Despite the encouraging demonstration in humans in
Nairobi of a safe DNA/MVA vaccine (Mwau et al., 2004),
there was a lack of a strong showing of immunogenicity, but
this DNA vaccine was built on only 365 AA of Gag and a
string of 25 overlapping CTL epitopes. Our DNA vaccine is
significantly (fourfold) larger (2386 amino acid residues)
and encodes HIV-1 Gag, Pol, Env, Tat, Rev, and Vpu.
Results from this preclinical nonhuman primate immuno-
genicity trail and others (Amara et al., 2001; Smith et al.,
2004a, 2004b) have demonstrated significant and broadly
reactive CD4 and CD8 cellular responses using a multi-gene
approach. Numerous epitopes throughout the HIV genome
participated in the cellular immune response and clearly
broad cellular responses are very important for limiting viral
escape (Barouch et al., 2002, 2003). Incorporating multiple
HIV-1 gene regions on the same DNA construct should
augment the prime boost combination and reduce the
likelihood of limited immunogenicity and viral escape to
single epitope.
As recently demonstrated in healthy low-risk volunteers
in Oxford and Nairobi, the overall DNA and MVA
approach, including the candidate DNA and MVA vaccines
by themselves and as a prime boost combination, has been
confirmed to be safe (Mwau et al., 2004). The additional
safety measures introduced into our vaccine construct
proved not to be disadvantageous and may be included in
the DNA prime without the need to strike a balance between
safety and effectiveness of the vaccine as both the height
and breadth of the elicited cellular response by the IC48-
primed animals were robust. Altering the original HIV
sequence by creating specific point mutations within Gag
and Pol was not detrimental to in vivo expression (data not
shown). The identical mutations in an HIV-1 subtype B
construct reduced viral RNA packaging within the VLPs
and completely eliminated viral RNA reverse transcriptase
activity (Smith et al., 2004b).
The production of noninfectious enveloped VLPs and
multiple antigenic forms may potentially improve the
effectiveness of a DNA/MVA vaccine and may provide
the best level of protection by controlling HIV-1 replication
and perhaps infection. We sought to optimize expression of
the DNA vaccine, not only in terms of high-level production
of HIV-1 proteins, but also with regard to assembly of VLPs
constructed from multiple HIV proteins. Our in vitro data
suggested that VLPs with matured cores may be an
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2004) and our findings in this immunogenicity trial support
these in vitro findings as the height of the immune response
was greater for mature VLPs. Shifting the qualitative
production of HIV products from an aggregate-forming
DNA to a VLP-forming DNA was not remarkable as these
constructs were similar in their ability to prime an MVA
boost (Smith et al., 2004a). However, including fusion-
competent mature VLPs by candidate DNA or other live-
vectored vaccine constructs may provide immunological
advantages for induction of protective cellular and humoral
responses against HIV-1. There may be an even greater
difference between the two DNA vaccines since the
efficiency of the priming by the two different DNA
constructs could be minimized by virtue of the highly
effective MVA booster.
The development and characterization of HIV-1 DNA
vaccines that generate a balance of these different antigenic
forms constructed from multiple HIV proteins may provide
distinct immunologic advantages and further advance
vaccine development. The level of virus-specific CD8+ T
cells induced by vaccination of macaques may indicate an
antiviral role for vaccine-elicited CD8+ T cell responses in
the animal model of vaccine efficacy. The production of
mature virus-like particles, which may behave similarly to
attenuated live-virus vaccines but without risk of integration
or causing AIDS, is clearly an obtainable goal for multi-
gene/multi-protein HIV-1 DNA vaccine approaches. It
remains to be determined from preclinical trials whether
either one of these DNA vaccines, when coupled with an
MVA booster, will provide protection from HIV-1 infection
or disease progression.Materials and methods
DNA immunogens
DNA constructs were made in the pGA1 expression
vector (GenBank accession no. AF425297) that includes
intron A in the promoter cassette and uses the CMV
immediate–early promoter and the bovine growth hormone
polyadenylation sequence to express RNAs (Chapman et al.,
1991; Ross et al., 2000). An incident recombinant HIV-1
subtype AG (CRF02_AG) strain IC0928 was reverse
transcribed (GenBank accession no. AY227361 and
AY227362), and fragments produced by DNA PCR were
cloned into the pGA1 expression vector (Ellenberger et al.,
2002, 2004). Construction and description of pGA1/IC48
(IC48) have been previously described (Ellenberger et al.,
2004). pGA1/IC1–90 (IC1–90) differs from IC48 by point
mutations in gag and pol. Briefly, IC1–90 lacks the
introduced point mutations in gag NC zinc fingers and pol
RT as previously described for IC48 (Ellenberger et al.,
2004; Smith et al., 2004a, 2004b). IC1–90 and IC48 also
differ in their protease sequence where there are twosubstitutions in IC1–90, an Arg-to-Gly substitution at
position 70 and Met-to-Leu substitution at position 90.
IC48 has a Gly-to-Val substitution at position 48 as
previously described. The protease mutations were made
using a site-directed mutagenesis kit (Stratagene, La Jolla,
CA) following the manufacturer’s protocol. All mutations
were confirmed by sequencing.
Recombinant MVA immunogen
A recombinant MVA expressing gag, pol, and env
regions derived from IC0928 will be described elsewhere
(Wyatt and Moss, unpublished data). Briefly, it was
constructed with gag–pol inserted into deletion III and a
truncated env into del II as described previously for MVA/
SHIV89.6 (Earl et al., 2002) with the modification that a
transient GFP marker for obtaining recombinant virus was
used, similar to the transient GUS described by Wyatt et al.
(2004).
Cell line and transient transfections
Human 293T cells, a human kidney-derived cell line,
were maintained in Dulbecco modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum.
293T cells were added at 106 cells/well of Costar 6-well
plates in 2 ml of DMEM growth medium and incubated for
24 h at 37 -C in a 5% CO2 humidified atmosphere. After 24
h, LipofectAmine2000 reagent (Invitrogen, Carlsbad, CA)
and plasmid DNA were mixed according to the manufac-
turer’s protocol and added to each well. Supernatants were
harvested 24 or 48 h following the addition of transfection
reagents.
Purification of particles
Following 24 h of transient transfection of 293T cells,
culture supernatants were recovered, clarified by centrifu-
gation at 200  g for 5 min, and 1 ml was layered on top of
10–50% sucrose gradients. Gradients of 10 ml consisting of
2 ml each of 50%, 40%, 30%, 20%, and 10% sucrose
solutions were added to ultraclear centrifuge tubes from
bottom to top. Gradients were centrifuged at 40,000 rpm for
16 h in SW41Ti rotor. Fractions of 1 ml were recovered, top
to bottom. Fraction aliquots were analyzed by HIV-1 p24-
antigen-capture assay.
Electron microscopy
Transfected 293T cells were fixed in the multi-well plate
using 1 ml of 2.5% glutaldehyde in 0.1 M cacodylate buffer
for 2 h at 4 -C. After three washes with the same buffer,
1.0% osmium tetroxide in 0.1 M cacodylate buffer was
added, incubated for 1 h, dehydrated through an ethanol
series, and embedded with Eponate 12 resin. Following
polymerization of the resin, the cells were sectioned en
D. Ellenberger et al. / Virology 340 (2005) 21–32 29face, stained with 4% uranyl acetate in water and lead
citrate, and observed on a Hitachi H-7500 transmission
electron microscope.
Antigen-capture assay
Assay was performed using an HIV-1 antigen-capture
EIA kit (Coulter, Hialeah, FL) according to the manufac-
turer’s instructions.
Env ELISA
Pooled human immunoglobulin anti-HIV (catalog no.
3957) was obtained from the National Institute of Allergy
and Infectious Diseases AIDS Research and Reference
Reagent Program (Rockville, MD). Env ELISAwas done as
previously described (Ellenberger et al., 2004).
Macaques and immunogenicity trial
Sixteen young adult male outbred rhesus macaques
(Macaca mulatta) of Indian origin were randomized by
weight into two vaccine groups of 8. The IC1–90 group
received 0.6 mg of IC1–90 DNA and the IC48 group
received 0.6 mg of IC48 DNA intramuscularly (IM) at
weeks 0, 8, and 26. DNA immunizations were delivered in
phosphate-buffered saline with a needle and syringe. A total
of 3 injections were delivered to the upper lateral right thigh
in a volume of 1 ml/injection. Fifteen weeks following the
3rd DNA immunization (week 41), all animals received 1 
108 pfu of a modified vaccinia Ankara virus (MVA/HIV)
booster IM using a needle and syringe in the upper lateral
right thigh. The MVA immunization was delivered in
phosphate-buffered saline in a volume of 1 ml. Injection
sites were monitored for local inflammatory reactions.
Humoral responses
Western blot analysis of whole virus lysate and sucrose-
purified VLP was performed as previously described
(Sambrook et al., 1989). Whole virus lysate (IC0928)
was run on 4–15% gradient SDS gel and transferred to
nitrocellulose. Plasma samples were diluted 1:100 in
blocking buffer. The secondary antibody was anti-human
IgG (Fab)-phosphatase and detection was completed by
using the BCIP/NBT phosphatase substrate system (KPL,
Gaithersburg, MD) according to manufacturer’s instruc-
tions. Analysis of sucrose-purified VLP was completed
using rabbit polyclonal anti-p24 (catalog no. 4250) which
was obtained from the National Institute of Allergy and
Infectious Diseases AIDS Research and Reference Reagent
Program. HIV-1 Gag protein bands were visualized using
the ECL Western blotting detection reagent (Amersham
Pharmacia Biotech, Piscataway, NJ) as described by the
manufacturer. Expression levels were determined using a
phosphoimager.To measure the levels of Env IgG in sera of immunized
monkeys, 96-well U-bottom plates were coated with sheep
antibody to the C-terminus of gp120 followed by purified
CRF02–AG gp140 as previously described (Earl et al.,
2002). The time of incubation of serum dilutions was
increased from 2 h to overnight for enhanced sensitivity of
the ELISA.
Neutralization was measured as a function of reductions
in luciferase reporter gene expression after a single round of
infection in TZM-bl cells as described (Montefiori, in
press). TZM-bl cells were obtained from the NIH AIDS
Research and Reference Reagent Program, as contributed by
John Kappes and Xiaoyun Wu. Briefly, 200 TCID50 of
virus was incubated with serial threefold dilutions of serum
sample in triplicate in a total volume of 150 Al for 1 h at
37 -C in 96-well flat-bottom culture plates. Freshly trypsi-
nized cells (10,000 cells in 100 Al of growth medium
containing 75 Ag/ml DEAE dextran) were added to each
well. Indinavir was added at a final concentration of 1 AM to
prevent replication in the case of HIV-1 MN. One set of
control wells received cells + virus (virus control) and
another set received cells only (background control). After a
48-h incubation, 100 Al of cells was transferred to a 96-well
black solid plates (Costar) for measurements of lumines-
cence using Bright Glo substrate solution as described by
the supplier (Promega). An assay stock of virus pseudo-
typed with gp160 from the CRF02–AG vaccine strain was
prepared by transfection in 293T cells and titrated in TZM-
bl cells. The assay stock of HIV-1 MN was prepared in H9
cells.
Peptide pools
HIV-1 recombinant subtype CRF02–AG peptides were
15mers overlapping by 11 derived from the vaccine strain.
Peptides were assembled into pools containing approx-
imately 25 peptides. Peptides were dissolved in DMSO at
50–100 mg/ml and stock solutions maintained at 70 -C.
Peptide working solutions were kept at 20 -C for 1 week.
T cell assays
ELISPOT assays were done as previously described
(Amara et al., 2001, 2002), except that 2 Ag/ml of antibody
to human CD28 and CD49d (Becton Dickinson, San Jose,
CA) was included in incubations (Waldrop et al., 1998).
Purified PBMC were plated in duplicate in 96-well plates at
2  105 cells/well with peptide pools used at a final
concentration of 10 Ag/ml for each peptide. Four wells
received only media. Plates were incubated at 37 -C, 5%
CO2 for 36 h, and spots counted using an ELISPOT reader.
Background was set at 2 the average of the negative
control wells plus 10. This background value was subtracted
from the raw counts of the peptide wells before conversion
to 1 million PBMC. Only ELISPOT counts of twice the
background (>100) were considered significant.
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and IL-2 have been described previously (Amara et al.,
2001, 2002). For those assays, one million PBMC were
resuspended in 100 Al of RPMI in a 5-ml polypropylene
tube and stimulated with 100 Ag/ml of the peptide pool in
the presence of anti-CD28 and anti-CD49d antibody at a
final concentration of 1 Ag/ml. The cells were incubated at
37 -C, in a tissue culture incubator at an angle of 5- in 100
Al. At 2 h, 900 Al of medium with 10 Ag of Brefeldin Awas
added and the incubation continued for an additional 4 h.
Cells were then stained for CD3, CD8, CD69, IFN-g, and
IL-2 fixed with 1% formaldehyde in PBS, and acquired
within 24 h on a FACScaliber (Becton Dickinson, San Jose,
CA). Approximately 150,000 lymphocytes were acquired
for each sample. Data were analyzed using FloJo software
(Tree Star, Inc., San Carlos, CA).
Statistical analysis
The Wilcoxon test for independent samples and signed-
rank test were used for comparison of immunogenicity tests
from groups primed with the two DNA vaccines. A mixed-
effects model using a linear regression of the aggregate
ELISPOT values on group (IC-48 or IC1–90) and time with
monkeys as the random effect was used. Also, a mixed-
effects linear regression model was used for testing
responses of CD4 versus CD8 T cells, T cell responses
against Gag versus Env, and IFN-g and IL-2 expression.Acknowledgments
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